Purpose: Since the mRNA technology used to manufacture Pfizer-BioNTech COVID-19 Vaccine is new, it is still difficult to predict its consequences. However, many young people, especially in developing countries, think that they are less susceptible to severe infection with the Coronavirus 2 (SARS-CoV-2), Therefore, they do not prefer to take the COVID-19 vaccines. Accordingly, studies in this aspect are necessary to increase people’s awareness of the acceptance of vaccination, especially for the youth. Patients and Methods: This study was conducted on healthy young adults of both sexes. Participants (n = 81) were received two doses of the Pfizer-BioNTech COVID-19 Vaccine. A paper questionnaire was prepared, the survey asks about the side effects related to receiving the Vaccine. All participants completed the questionnaire twice, once after the first dose and again after the second dose. Data were collected and statistically analyzed. Results: The most common side effects were Muscle pain, Tiredness, Headache, and Fever. Less common side effects were Chills, Fainted, Breathlessness, and Coughing. Rare side effects include nausea and vomiting, Diarrhea, Anaphylactic Reaction, and Swollen Lymph Nodes. Side effects that are strongly associated with females are Headache, and Joint pain, for males, Anaphylactic reaction. The study revealed a significant difference between the number of females (96.5%) and males (85%) who suffered from the side effects of the Pfizer-BioNTech COVID-19 Vaccine (P = 0.033). Conclusion: Most of the side effects reported in our study were consistent with Pfizer’s fact sheet for recipients and caregivers. Through our follow-up to the participants in the study, we noticed that the reported side effects were not too bad, and they were able to carry out their daily activities, so we recommend taking the vaccine, especially for young people.
Coronavirus 2 (SARS-CoV-2) broke out at the end of 2019, and soon after, the virus spread, causing a high mortality and morbidity rate worldwide [
Several types of COVID-19 vaccines have been developed to combat this pandemic, including Pfizer-BioNTech, Moderna, Sinopharm, Sinovac, Sputnik V, Janssen (Johnson & Johnson’s) and AstraZeneca. These vaccines have been verified to be effective to prevent the infection of COVID-19 at varying efficacy, each kind of vaccine has a subtle structure, pros and cons with respect to efficacy, immunogenicity and safety [
COVID-19 vaccine-specific mild adverse reactions have been recorded after receiving first, second or both doses include: fever, headache, myalgia, pain at injection site, arthralgia, fatigue, chills and lymphadenopathy, etc with variation either mild or sever among given vaccines [
The Pfizer-BioNTech COVID-19 Vaccine was approved by the US Food and Drug Administration (FDA) on December 11, 2020, for emergency use in individuals 16 years of age and older [
Since the mRNA technology used to make Pfizer-BioNTech COVID-19 Vaccine is new, it is still difficult to predict its consequences. Additionally, rumors around the useless of vaccine effectiveness and the adverse reactions among young people, especially in developing countries, obstacle the efforts COVID-19 vaccine campaign to reach the community. Accordingly, studies in this aspect are necessary to increase people’s awareness of the acceptance of vaccination, especially for the youth. The current study aims to follow up and short-term side effects after receiving the Pfizer-BioNTech COVID-19 Vaccine in a sample of young people. Also studying the correlations between side effects and which groups are most susceptible to side effects within the study sample.
This study was conducted after approval from Scientific Research Ethics Committee (SREC), Faculty of Dentistry, Benghazi University, Libya (No. 074) Written approval (Informed consent) was obtained from all study participants. The study was conducted at the Faculty of Pharmacy, Omar Al-Mukhtar University, Al-Bayda, Libya.
Participants accepted in this study fulfilled the following criteria “youth people, both genders, healthy/or participants with the clinically controlled disease, did not have any respiratory disease, pregnant and breastfeeding women are not allowed, participants will only be included after signing the voluntary (Informed Consent Form)”. The sample consisted of 81 participants, including 69 women and 12 men with ages ranging from 19 to 25 years, who attended the Faculty of Pharmacy, Omar Al-Mukhtar University, Al-Bayda, Libya, between July 2021, and September 2021.
All participants were subjected to the following:
A detailed assessment of history, with a special focus on age, sex, height, body Weight, Diabetes mellitus, Systolic blood pressure Diastolic blood pressure.
All participants received two doses of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), manufactured by: Pfizer, Inc., and BioNTech.
Undergo prepared survey twice at baseline (1 - 14 days after the first dose), and final (1 - 14 days after the second dose).
A paper questionnaire was prepared, written in Arabic, and scientific terms were clarified in the public language. The questionnaire was delivered to each participant, and a filling method was clarified. Participants were also provided with the phone numbers of the researchers conducting the study, to answer any questions regarding the questionnaire. Participants were volunteers and were not given any incentive.
The survey asks about the side effects related to receiving the Pfizer-BioNTech COVID-19 Vaccine. Participants were also asked to mention any other symptoms not mentioned in the questionnaire.
The questionnaire includes questions about if any of the following symptoms occur: (Muscle pain, Tiredness, Headache, Fever, Swelling, joint pain, Tingling, Itching, Chills, Fainted, Breathlessness, Coughing, Redness, Nausea and vomiting, Diarrhea, Anaphylactic Reaction, Swollen Lymph Nodes, and Onset of Symptoms).
The “Mann Whitney test” was used to analyze differences between any two groups in the study. The correlation analysis between change in one side effect caused by Pfizer-BioNTech COVID-19 Vaccine and other parameters (
All procedures of this study were approved and regularly controlled by the SREC, Faculty of Dentistry, Benghazi University, Libya (No. 074), and all experiments were performed by the guidelines and regulations of this committee. All the procedures were also carried out in full accordance with the Council for International Organizations of Medical Sciences (CIOMS) ethical guidelines 2017 [
Participants characteristics, number of doses, and reported side effects
A number of 81 people participated in this study, all of them were students of the Faculty of Pharmacy, Omar Al-Mukhtar University, Al-Bayda, Libya, males were the minority of participants (12, 14.8%), which actually represent the percentage of male students studying at the Faculty of Pharmacy in the different academic years ranges from 10% to 14%, compared to the percentage of female students. It was found that the participants average age was (21.5, ±1.7 years), with mean body mass index (23.1, ±3.5 kg/m2), mean systolic blood pressure was (118.5, ±6.3 mmHg), and mean diastolic blood pressure was (78.2, ±5.3 mmHg). Two of the participants were diabetics (2.5%). All study participants (81, 100%) had received their first Pfizer-BioNTech COVID-19 Vaccine dose, while (54, 66.6%) had received both doses. After they received their first dose, (75, 92.6%) of the participants reported the appearance of side effects, and after they received their second dose, (53, 98.1%) of the participants reported the appearance of side effects. After both doses, the incidence of side effects was higher in females than in males, which were (96.5%), and (85.0%) respectively. Please take note of the following items when proofreading spelling and grammar:
Reported Pfizer-BioNTech COVID-19 Vaccine Side Effects and their Correlation with the first and second doses
The results showed an increase in the number of participants who were suffering from side effects after receiving the second dose of the Pfizer-BioNTech COVID-19 Vaccine (53, 98.1%), compared to those who reported side effects after receiving the first dose (75, 92.6%). No significant differences were observed when comparing each side effect individually after the first and second dose, except for Chills (P = 0.001) and Breathlessness (P = 0.034) (
| Participants | ||||
|---|---|---|---|---|
| Baseline (N = 81) | Final (N = 54) | P-value | P-value summary | |
| Age (years), mean ± SD | 21.5 (±1.7) | 21.6 (±1.8) | 0.854 | Ns |
| Men, n (%) | 12 (14.8) | 8 (14.8) | >0.999 | Ns |
| BMI (kg/m2), mean ± SD | 23.1 (±3.5) | 23.2 (±3.8) | 0.876 | Ns |
| Diabetes mellitus, n (%) | 2 (2.5) | 1 (1.9) | 0.819 | Ns |
| Systolic BP (mmHg), mean (± SD) | 118.5 (±6.3) | 117.8 (±7.6) | 0.544 | Ns |
| Diastolic BP (mmHg), mean (± SD) | 78.2 (±5.3) | 77.5 (±5.8) | 0.558 | Ns |
| Muscle pain, n, (%) | 57 (70.4) | 33 (61.1) | 0.351 | Ns |
| Tiredness, n (%) | 46 (56.8) | 36 (66.7) | 0.283 | Ns |
| Headache, n (%) | 43 (53.1) | 34 (63.0) | 0.289 | Ns |
| Fever, n (%) | 35 (43.2) | 32 (59.3) | 0.080 | Ns |
| Swelling, n (%) | 28 (34.6) | 20 (37.0) | 0.854 | Ns |
| Joint pain, n (%) | 24 (29.6) | 20 (37.0) | 0.453 | Ns |
| Tingling, n (%) | 22 (27.2) | 16 (29.6) | 0.845 | Ns |
| Itching, n (%) | 20 (24.7) | 16 (29.6) | 0.555 | Ns |
| Chills, n (%) | 12 (14.8) | 22 (40.7) | 0.001 | ** |
| Fainted, n (%) | 9 (11.1) | 9 (16.7) | 0.440 | Ns |
| Breathlessness, n (%) | 6 (7.4) | 11 (20.4) | 0.034 | * |
| Coughing, n (%) | 8 (9.9) | 8 (14.8) | 0.423 | Ns |
| Redness, n (%) | 6 (7.4) | 8 (14.8) | 0.248 | Ns |
| Nausea and vomiting, n (%) | 7 (8.6) | 4 (7.4) | >0.999 | Ns |
| Diarrhea, n (%) | 3 (3.7) | 4 (7.4) | 0.437 | Ns |
| Anaphylactic Reaction, n (%) | 2 (2.5) | 1 (1.9) | 0.819 | Ns |
| Swollen Lymph Nodes, n (%) | 0 (0.0) | 2 (3.7) | 0.158 | Ns |
| Onset of Symptoms (day), mean (± SD) | 1.4 (±0.9) | 1.5 (±0.9) | 0.259 | Ns |
The more “*” in the p-value summary, the greater significance level. While Ns mean non significance; ±SD: Standard Deviation; BP: Blood Pressure.
Correlation effects between side effects and the participant’s gender
In general, the results showed a significant difference between the number of females (96.5%) and males (85%) who suffered from the side effects of the Pfizer-BioNTech COVID-19 Vaccine (P = 0.033). Male had the highest incidence of muscle pain (70%) compared to females (66.1%) (P = 0.8027). (62.6 %) of females reported feeling tired, compared to (50%) of males (P = 0.326). For headache, the results showed a significant difference between females and males, Where the percentage of females was (60.9%), compared to (35%) for males (P = 0.048). Finally, there were no clear differences in the percentage of fever between females and males, as it was (49.6%) for females and (50%) for males (P > 0.999). Results are presented in (
Spearman Correlation Test was performed on gender and the top four reported side effects (Muscle pain, Tiredness, Headache, and Fever) to find its correlation with each response marker separately. Only statistically significant results are shown.
Gender: Side effects that are strongly associated with females, but not in males, are Headache (r = −0.185, P = 0.031), Joint pain (r = −0.201, P = 0.031). For males, the significantly associated response markers which were not significant in females are Body mass index (r = 0.232, P = 0.006), and Anaphylactic reaction (r = 0.220, P = 0.010). 95% confidence interval. Results are presented in
Muscle pain: Spearman’s correlation coefficient analysis showed that negatively correlated with: Coughing (r = −0.226, P = 0.0081), Diarrhea (r = −0.189, P = 0.0282); and positively correlated with: Itching (r = 0.248, P = 0.003), Headache (r = 0.275, P = 0.001), Tiredness (r = 0.300, P = 0.0004), Fainted (r = 0.184, P = 0.0318), Tingling (r = 0.407, P > 0.0001), Onset of Symptoms (r = 0.183, P = 0.0336), 95% confidence interval. Results are presented in
| Response Marker | r (95% confidence interval) | P-value | P-value summary |
|---|---|---|---|
| Headache | −0.185 (−0.343 to −0.017) | 0.0311 | * |
| joint pain | −0.201 (−0.357 to −0.033) | 0.0194 | * |
| BMI | 0.232 (0.066 to 0.386) | 0.0067 | ** |
| Anaphylactic Reaction | 0.220 (0.053 to 0.375) | 0.0103 | * |
| Response Marker | r (95% confidence interval) | P-value | P-value summary |
|---|---|---|---|
| Itching | 0.248 (0.083 to 0.400) | 0.0036 | ** |
| Headache | 0.275 (0.111 to 0.424) | 0.0012 | ** |
| Tiredness | 0.300 (0.138 to 0.446) | 0.0004 | *** |
| Coughing | −0.226 (−0.381 to −0.060) | 0.0081 | ** |
| Diarrhea | −0.189 (−0.346 to −0.020) | 0.0282 | * |
| Fainted | 0.184 (0.016 to 0.343) | 0.0318 | * |
| Tingling | 0.407 (0.256 to 0.539) | <0.0001 | **** |
| Onset of Symptoms | 0.183 (0.014 to 0.341) | 0.0336 | * |
Tiredness: Spearman’s correlation coefficient analysis showed that negatively correlated with: Body mass index (r = −0.223, P = 0.0091), Diastolic blood pressure (r = −0.263, P = 0.0020); and positively correlated with: Itching (r = 0.176, P = 0.0411), Fever (r = 0.403, P < 0.0001), Headache (r = 0.558, P < 0.0001), Muscle pain (r = 0.300, P = 0.0004), Breathlessness (r = 0.213, P = 0.0128), joint pain (r = 0.397, P < 0.0001), Fainted (r = 0.270, P = 0.0015), Tingling (r = 0.300, P = 0.0004), Chills (r = 0.397, P = 0.186), 95% confidence interval. Results are presented in
Headache: Spearman’s correlation coefficient analysis showed that negatively correlated with: Age (r = −0.178, P = 0.0384), Gender (r = −0.185, P = 0.0311); and positively correlated with: Itching (r = 0.286, P = 0.0008), Fever (r = 0.352, P < 0.0001), Muscle pain (r = 0.275, P = 0.0012), Tiredness (r = 0.558, P < 0.0001), Coughing (r = 0.225, P = 0.0085), Breathlessness (r = 0.194, P = 0.0241), joint pain (r = 0.411, P < 0.0001), Fainted (r = 0.252, P = 0.0031), Tingling (r = 0.243, P = 0.0044), 95% confidence interval. Results are presented in
| Response Marker | r (95% confidence interval) | P-value | P-value summary |
|---|---|---|---|
| BMI | −0.223 (−0.378 to −0.056) | 0.0091 | ** |
| Diastolic BP | −0.263 (−0.414 to −0.099) | 0.0020 | ** |
| Itching | 0.176 (0.007 to 0.335) | 0.0411 | * |
| Fever | 0.403 (0.251 to 0.536) | <0.0001 | **** |
| Headache | 0.558 (0.430 to 0.664) | <0.0001 | **** |
| Muscle pain | 0.300 (0.138 to 0.446) | 0.0004 | *** |
| Breathlessness | 0.213 (0.046 to 0.369) | 0.0128 | * |
| joint pain | 0.397 (0.244 to 0.530) | <0.0001 | **** |
| Fainted | 0.270 (0.106 to 0.420) | 0.0015 | ** |
| Tingling | 0.300 (0.138 to 0.447) | 0.0004 | *** |
| Chills | 0.186 (0.018 to 0.345) | 0.0300 | * |
| Response Marker | r (95% confidence interval) | P-value | P-value summary |
|---|---|---|---|
| Age | −0.178 (−0.337 to −0.009) | 0.0384 | * |
| Gender | −0.185 (−0.343 to −0.017) | 0.0311 | * |
| Itching | 0.286 (0.123 to 0.434) | 0.0008 | *** |
| Fever | 0.352 (0.195 to 0.492) | <0.0001 | **** |
| Muscle pain | 0.275 (0.111 to 0.424) | 0.0012 | ** |
| Tiredness | 0.558 (0.430 to 0.664) | <0.0001 | **** |
| Coughing | 0.225 (0.058 to 0.380) | 0.0085 | ** |
| Breathlessness | 0.194 (0.026 to 0.351) | 0.0241 | * |
| joint pain | 0.411 (0.261 to 0.543) | <0.0001 | **** |
| Fainted | 0.252 (0.087 to 0.404) | 0.0031 | ** |
| Tingling | 0.243 (0.078 to 0.396) | 0.0044 | ** |
Fever: Spearman’s correlation coefficient analysis showed that positively correlated with: Headache (r = 0.352, P < 0.0001), Tiredness (r = 0.403, P < 0.0001), joint pain (r = 0.226, P = 0.0083), Chills (r = 0.243, P = 0.0045), 95% confidence interval. Results are presented in
Since starting the global health crisis of COVID-19 pandemic in January 2020, precautionary measures have been taken by most countries to control SARS-CoV-2 transmission anticipating the rapid production of safe and effective vaccines [
Thus this study aimed to report and follow up on potential short term side effects of Pfizer vaccine for healthy young people from July to September 2021 at the Faculty of Pharmacy, Omar Al-Mukhtar University, Al-Bayda, Libya.
The side effects of the Pfizer-BioNTech COVID-19 Vaccine reported in this study showed an increase in the number of participants who were suffering from side effects after receiving the second dose with (53, 98.1%), compared to those who reported side effects after receiving the first dose (75, 92.6%). When comparing the second dose and the first dose of the vaccine, a report published by by the U.S FDA revealed that the frequency of local side effects was slightly higher after the second dose compared to the first dose [
According to the study conducted by Elnaem, M.H.; et al. 2021, about 40% of the side effects occurred more with the second dose, particularly those who received the Pfizer-BioNTech vaccine compared to those who received the Sinovac or AstraZeneca vaccine [
| Response Marker | r (95% confidence interval) | P-value | P-value summary |
|---|---|---|---|
| Headache | 0.352 (0.195 to 0.492) | <0.0001 | **** |
| Tiredness | 0.403 (0.251 to 0.536) | <0.0001 | **** |
| joint pain | 0.226 (0.059 to 0.380) | 0.0083 | ** |
| Chills | 0.243 (0.077 to 0.395) | 0.0045 | ** |
Notably, the most frequently reported adverse reactions in the current study were (Muscle pain (66.7%), Tiredness (60.7%), Headache (57.0%), and Fever (49.6%) these were common and consistent with other studies as Ahlam Alghamdi et al.; 2021 stated that tiredness, headache, and fever were observed to be the most common side effects of the vaccine [
In a research study conducted in Italy by Giuseppe Lippi.; 2021, fever was the most frequent mild side effect after administration of Pfizer vaccines (13.2%), followed by headache (10.3%), myalgia (8.7%), pain at injection site (8.3%), arthralgia (7.9%), and tiredness [
A focus on the gender-related differences concerning adverse reactions involved in the present study, which showed that, the occurrence of the side effects in females (96.5%) were more likely than males (85%) and were similar to those reported by previous studies that have shown that, men were less likely to suffer adverse side effects than women [
Onset of symptoms in this study were quit similar after both doses, in first dose (baseline) were started to appear less than 24 hrs 6 (7.4%), 24 to 72 hrs 57 (70.4%) and on the third day or later 18 (22.2%). While the symptoms after the second dose (final) were started to appear less than 24 hrs 1 (1.85%), 24 to 72 hrs 38 (70.3%) and on the third day or later 15 (27.7%). The result of another study was completely different in terms of the time of appearance of side effects, especially between the first and second day, and the time of their appearance was as follow: First day 257 (84%), Second day 47 (15%) and on the third day or later 3 (1%) [
The most common reported side effects after both doses of the Pfizer-BioNTech COVID-19 vaccine among pharmacy students were Muscle pain, Tiredness, headache, and fever. These reported short-term side effects of vaccines were highly consistent with the data published in Pfizer fact sheet in terms of their association with the younger age group and the second dose. Although the several side effects were reported throughout the present study, it is noticed that the reported side effects were common but not serious, and participants were able to attend their university classes and carry out their daily activities, so we recommend taking the vaccine, especially for young people.
Taher I. Shailabi: Methodology, Conceptualization, Survey preparation, data collection, Funding acquisition, and Writing—original draft & editing. Nagat H. Bubtina: Validation, Writing—review & editing, Supervision, and Investigation. Elham O. Borwis, Naeima Betamar and Nisreen Saed Majeed: Writing—review & editing. Guma Abdeldaim: Review & Editing, Supervision.
We have to express our appreciation to the students of the Faculty of Pharmacy, Omar Al-Mukhtar University, Al-Bayda, Libya, for their voluntary participation in this study.
The authors declare no conflicts of interest regarding the publication of this paper.
Shailabi, T.I., Borwis, E.O., Majeed, N.S., Bubtina, N.H., Betamar, N. and Abdeldaim, G. (2022) Side Effects of Pfizer-BioNTech COVID-19 Vaccine among Libyan Young Adults: Observational Study. Journal of Biosciences and Medicines, 10, 33-45. https://doi.org/10.4236/jbm.2022.101005
CDC, Centers for Disease Control and Prevention; SARS-CoV-2, Coronavirus 2; CIOMS, Council for International Organizations of Medical Sciences; FDA, Food and Drug Administration; WHO, World Health Organization; SREC, Scientific Research Ethics Committee.